Keywords: لوسمی میلوئیدی مزمن (CML); Chronic myeloid leukemia (CML); chromosomal abnormalities in Philadelphia negative cells; monosomy 7; trisomy 8; TKI treatment;
مقالات ISI لوسمی میلوئیدی مزمن (CML) (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
siRNA/lipopolymer nanoparticles to arrest growth of chronic myeloid leukemia cells in vitro and in vivo
Keywords: لوسمی میلوئیدی مزمن (CML); BCR-ABL; Chronic myeloid leukemia (CML); Fusion gene; Gene therapy; Lypopolymer carrier; Non-viral delivery; RNAi; siRNA delivery;
microRNA-199a/b-5p enhance imatinib efficacy via repressing WNT2 signaling-mediated protective autophagy in imatinib-resistant chronic myeloid leukemia cells
Keywords: لوسمی میلوئیدی مزمن (CML); Imatinib resistance; Autophagy; miR-199a-5p; miR-199b-5p; WNT2; Chronic myeloid leukemia (CML); 3-MA; 3-methyladenine; AVO; acidic vesicular organelle; CML; chronic myeloid leukemia; CQ; chloroquine; DMSO; dimethyl sulfoxide; HRP; horseradish peroxidase;
SHC004-221A1, a novel tyrosine kinase, potently inhibits T315I mutant BCR-ABL in chronic myeloid leukemia
Keywords: لوسمی میلوئیدی مزمن (CML); Imatinib mesylate (PubChem CID: 123596); Dasatinib (PubChem CID: 3062316); Ponatinib (PubChem CID: 24826799); Nilotinib (PubChem CID: 644241); SHC004-221A1; Chronic myeloid leukemia (CML); BCR-ABL; T315I mutation;
Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors
Keywords: لوسمی میلوئیدی مزمن (CML); Chronic myeloid leukemia (CML); Tyrosine kinase inhibitor (TKI); BCR-ABL1; Treatment-free remission (TFR); Drug resistance; Mutation;
Phosphorylation of spleen tyrosine kinase at tyrosine 348 (pSyk348) may be a marker of advanced phase of Chronic Myeloid Leukemia (CML)
Keywords: لوسمی میلوئیدی مزمن (CML); Chronic Myeloid Leukemia (CML); Spleen tyrosine kinase (Syk); pSyk348; Flow cytometry; Dasatinib
Preclinical model for identification of therapeutic targets for CML offers clues for handling imatinib resistance
Keywords: لوسمی میلوئیدی مزمن (CML); Chronic myeloid leukemia (CML); Actin; RhoGTPases; Formyl peptide receptors (FPR); Signal transduction
Celecoxib sensitizes imatinib-resistant K562 cells to imatinib by inhibiting MRP1-5, ABCA2 and ABCG2 transporters via Wnt and Ras signaling pathways
Keywords: لوسمی میلوئیدی مزمن (CML); Imatinib mesylate; Chronic myeloid leukemia (CML); ABC transporters; Cyclooxygenase-2 (COX-2); Celecoxib;
Interferon decreases VEGF levels in patients with chronic myeloid leukemia treated with imatinib
Keywords: لوسمی میلوئیدی مزمن (CML); Vascular Endothelial Growth Factor (VEGF); Imatinib; Chronic myeloid leukemia (CML); Angiogenesis; Interferon-alpha;
Decreased microRNA-30a levels are associated with enhanced ABL1 and BCR-ABL1 expression in chronic myeloid leukemia
Keywords: لوسمی میلوئیدی مزمن (CML); Chronic myeloid leukemia (CML); miR-30a; BCR-ABL1; Tumor suppressor; Cell proliferation; Cell cycle;
CUEDC2 sensitizes chronic myeloid leukemic cells to imatinib treatment
Keywords: لوسمی میلوئیدی مزمن (CML); CUEDC2; K562; Chronic myeloid leukemia (CML); Imatinib; NF-κB;
Molecular Monitoring of BCR-ABL Transcripts after Allogeneic Stem Cell Transplantation for Chronic Myeloid Leukemia
Keywords: لوسمی میلوئیدی مزمن (CML); Allogeneic hematopoietic stem cell transplantation (HSCT); Chronic myeloid leukemia (CML); BCR-ABL; Minimal residual disease (MRD)
5â²-OH-5-nitro-Indirubin oxime (AGM130), an Indirubin derivative, induces apoptosis of Imatinib-resistant chronic myeloid leukemia cells
Keywords: لوسمی میلوئیدی مزمن (CML); Chronic myeloid leukemia (CML); Indirubin; Imatinib; K562; Cyclin-dependent kinase (CDK);
Physician’s guide to the clinical management of adverse events on nilotinib therapy for the treatment of CML
Keywords: لوسمی میلوئیدی مزمن (CML); Chronic myeloid leukemia (CML); Tyrosine kinase inhibitor (TKI); BCR-ABL; Nilotinib; Imatinib
Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed
Keywords: لوسمی میلوئیدی مزمن (CML); Chronic myeloid leukemia (CML); Oral medication; Imatinib; Adherence; Compliance;
Hsp90 cleavage by an oxidative stress leads to its client proteins degradation and cancer cell death
Keywords: لوسمی میلوئیدی مزمن (CML); Protein chaperone Hsp90; Oxidative stress; Ascorbate-driven menadione redox cycling; Chronic myeloid leukemia (CML); K562 cells; Bcr-Abl oncogene
Identification and structural comparison of deleterious mutations in nsSNPs of ABL1 gene in chronic myeloid leukemia: A bio-informatics study
Keywords: لوسمی میلوئیدی مزمن (CML); Chronic myeloid leukemia (CML); ABL1 gene; nsSNP; 3′ UTR region; Deleterious mutations; SIFT; PolyPhen; Modeled structure; Stabilizing residue
Stochastic modeling of cellular colonies with quiescence: An application to drug resistance in cancer
Keywords: لوسمی میلوئیدی مزمن (CML); Stochastic modeling; Chronic myeloid leukemia (CML); Cancer therapy; Cell cycle; Imatinib; Evolution
Abnormal expression of the programmed cell death 5 gene in acute and chronic myeloid leukemia
Keywords: لوسمی میلوئیدی مزمن (CML); Acute myeloid leukemia (AML); Chronic myeloid leukemia (CML); Programmed cell death 5 (PDCD5); Real-time quantitative reverse transcription polymerase chain reaction (RQ-RT-PCR); Apoptosis; Imatinib mesylate
Effect of glycosylphosphatidylinositol specific phospholipase D gene expression levels on complement mediated killing of leukemic cells in patients with chronic myeloid leukemia
Keywords: لوسمی میلوئیدی مزمن (CML); CD55; CD59; Gene expression; Glycosylphosphatidylinositol-specific phospholipase D; Chronic myeloid leukemia (CML);
Review of the literature on benzene exposure and leukemia subtypes
Keywords: لوسمی میلوئیدی مزمن (CML); Benzene; Acute myeloid leukemia (AML); Chronic myeloid leukemia (CML); Acute lymphocytic leukemia (ALL); Chronic lymphocytic leukemia (CLL); Case-control; Cohort;